Oral peptide formulations have been the long-running drug-delivery challenge in the field. Most peptides degrade in the gut or fail to cross the intestinal epithelium at therapeutic dose. The successful examples — oral semaglutide, oral Wegovy — depend on salt-permeation enhancers like SNAC.
Programmes covered on this site: oral semaglutide and oral Wegovy, Vivtex's permeability platforms, Biocon's oral insulin work, Boehringer's gut-targeted peptide formulations, and the small-molecule oral GLP-1 alternatives (Foundayo / orforglipron) that sidestep the peptide-stability problem altogether.
Stories here cover platform readouts and the partnership deals around them. See #oral-peptide for the singular tag and #drug-delivery for broader delivery technology.
AJMC ran a consumer-grade FAQ on oral peptides covering bioavailability (typically <1% even with optimized formulations), delivery technologies (SNAC for oral semaglutide, liposomal systems, lipidation as in liraglutide and insulin detemir), and the safety distinction between FDA-approved oral peptides and the wave of unverified products. The piece sits alongside the AMA's late-April primer on injectable peptides and STAT, Scientific American, Washington Post, and ABC News coverage from earlier in the year — collectively building the public-facing safety narrative ahead of the July 23–24 PCAC meeting. The FAQ explicitly flags the FDA expert-panel review and the gap between Category 2 removal and FDA approval.
The Drug Discovery Chemistry Oral & Macrocyclic Peptides Summit (April 14-15, San Diego) convenes as 66 cyclic peptide drugs have gained global approval and the field races to solve oral bioavailability. Key advances include Chugai's Luna18 achieving 21-47% oral bioavailability and Merck's macrocyclic PCSK9 inhibitor enlicitide delivering injectable-level results in pill form.
A comprehensive review in Frontiers in Drug Delivery examines the barriers to oral peptide bioavailability — enzymatic degradation, poor membrane permeability, and first-pass metabolism — and maps emerging solutions including permeation enhancers, nanoparticle encapsulation, mucoadhesive systems, and microRNA-based approaches that are advancing toward clinical translation.
OrbiMed-incubated startup revealed $89M in funding to develop oral peptide drugs with biologic-level efficacy. Lead program targets asthma and is on track for clinical trials.
Pinnacle closed an oversubscribed $89M Series B (total $134M) to advance AI-driven oral peptide therapeutics into clinical trials, focusing on immunology and cardiometabolic diseases.